BridgeBio
6
34M
4
0.86
2
0.33
2
- Areas of investment
Summary
BridgeBio appeared to be the Corporate Investor, which was created in 2014. The fund was located in North America if to be more exact in United States. The main department of described Corporate Investor is located in the Palo Alto.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 1 or 4 of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Alternative Medicine. Among the most popular portfolio startups of the fund, we may highlight QED Therapeutics, PellePharm, Eidos Therapeutics.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the BridgeBio, startups are often financed by Third Rock Ventures, Sanofi, Cowen Group. The meaningful sponsors for the fund in investment in the same round are Cormorant Asset Management, Cowen Group, Casdin Capital. In the next rounds fund is usually obtained by Perceptive Life Sciences, LEO Pharma, Cowen Group.
The current fund was established by Neil Kumar.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2018. This BridgeBio works on 11 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in less than 2 investment rounds annually. Speaking about the real fund results, this Corporate Investor is 20 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 2
- Exits
- 2
- Rounds per year
- 0.86
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (6)
- Therapeutics (4)
- Biopharma (4)
- Health Care (3)
- Pharmaceutical (2) Show 2 more
- Investments by region
-
- United States (6)
- Peak activity year
- 2018
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 3B
- Group Appearance index
- 0.67
- Avg. company exit year
- 8
- Avg. multiplicator
- 81.94
- Strategy success index
- 0.71
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| MyoKardia | 30 Apr 2015 | Biotechnology, Health Care, Medical, Therapeutics, Biopharma | Early Stage Venture | 46M | United States, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.